EMA Acknowledges Persistent Sexual Dysfunction After SSRIs & SNRIs
RxISK (Dr David Healy group)
rxisk.org2019-06
Summary (paraphrased)
RxISK's account of how its 2018 petition on PSSD and PGAD led to the EMA/PRAC review of sexual dysfunction after SSRI/SNRI discontinuation. It describes the 22 signatories, the submission of 82 named patient reports (32 with supporting letters from health professionals), and reproduces the EMA letters of May 2019 in which PRAC concluded that sexual dysfunction can be long-lasting in some patients even after treatment withdrawal. It also notes parallel outreach: the FDA petition remaining undecided, Health Canada requesting the named reports in January 2019, and no separate MHRA response being expected.
Why it’s in the corpus
The primary historical record of the patient-research campaign behind the 2019 EMA decision — how named (non-anonymous) reports were used to overcome the credibility problem of spontaneous reports. Pairs with the corpus's existing EMA-2019 event entry.
Related records
- Peer-reviewed paper
Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases
Healy, David; Le Noury, Joanna; Mangin, Dee · International Journal of Risk & Safety in Medicine · 29(3-4):125-134
Drawing on reports submitted to the RxISK.org adverse-event site, the authors assembled 300 cases of persistent sexual difficulty from 37 countries after treatment with serotonin reuptake inhibiting antidepressants, finasteride-type drugs, or isotretinoin…
CROSS-0012018PFSPSSDPRSDCore corpus - Peer-reviewed paper
One hundred and twenty cases of enduring sexual dysfunction following treatment
Hogan, C.; Le Noury, J.; Healy, D.; Mangin, D. · International Journal of Risk & Safety in Medicine · 26(2):109-116
Early case series of 120 reports of enduring sexual dysfunction following drug treatment, drawn from pharmacovigilance data, helping establish the phenomenon before formal criteria existed.
CROSS-0032014PSSDCore corpus - Peer-reviewed paper
Citizen petition: Sexual side effects of SSRIs and SNRIs
David Healy · International Journal of Risk & Safety in Medicine
This is the published text of a citizen petition asking the US FDA to require boxed warnings and label changes for all SSRI and SNRI products regarding persistent sexual dysfunction after discontinuation. The petition marshals the history of regulatory…
LIT-0202018PSSDLiterature sweep · Oct 2026